Novartis Exelon Promotion Cited By FDA For Unsubstantiated Superiority Claims To Aricept
This article was originally published in The Pink Sheet Daily
Executive Summary
Professional file card for the Alzheimer's medication is misleading because it is based on an inadequate study, FDA warning letter says.
You may also be interested in...
DoJ, Congress Want Ad Oversight: FDA Sounds Ready To Respond
The Department of Justice's level of interest in drug industry promotional issues seems to be increasing, FDA Division of Drug Marketing, Advertising & Communications Director Tom Abrams told the Food & Drug Law Institute advertising and promotion conference Sept. 8
DDMAC Letter Cites Pfizer Geodon Ad For Implying Superiority To Haloperidol
FDA also points to the journal ad’s lack of discussion of specific warnings for metabolic side effects and movement disorders.
DDMAC Letter Cites Pfizer Geodon Ad For Implying Superiority To Haloperidol
FDA also points to the journal ad’s lack of discussion of specific warnings for metabolic side effects and movement disorders.